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Background: Fungal load quantification is a critical component of fungal community analyses. Limitation of current
approaches for quantifying the fungal component in the human microbiome suggests the need for new
broad-coverage techniques.
Methods: We analyzed 2,085 18S rRNA gene sequences from the SILVA database for assay design. We generated
and quantified plasmid standards using a qPCR-based approach. We evaluated assay coverage against 4,968
sequences and performed assay validation following the Minimum Information for Publication of Quantitative
Real-Time PCR Experiments (MIQE) guidelines.
Results: We designed FungiQuant, a TaqManW qPCR assay targeting a 351 bp region in the fungal 18S rRNA gene.
Our in silico analysis showed that FungiQuant is a perfect sequence match to 90.0% of the 2,617 fungal species
analyzed. We showed that FungiQuant’s is 100% sensitive and its amplification efficiencies ranged from 76.3% to
114.5%, with r2-values of >0.99 against the 69 fungal species tested. Additionally, FungiQuant inter- and intra-run
coefficients of variance ranged from <10% and <20%, respectively. We further showed that FungiQuant has a limit
of quantification 25 copies and a limit of detection at 5 copies. Lastly, by comparing results from human-only
background DNA with low-level fungal DNA, we showed that amplification in two or three of a FungiQuant
performed in triplicate is statistically significant for true positive fungal detection.
Conclusions: FungiQuant has comprehensive coverage against diverse fungi and is a robust quantification and
detection tool for delineating between true fungal detection and non-target human DNA.Background
Fungi are among the most diverse eukaryotic organisms
on Earth, with nearly 10,000 named fungal species and an
estimated 1.5 to 5 million species that are yet to be defined
[1,2]. Fungi are also recognized as an important element
in human microbiome research, clinical medicine, and as
emerging pathogens [3-8]. However, methodological chal-
lenges have limited scientists’ and clinicians’ ability to
detect and measure fungal abundance.
Currently, fungal detection is performed through cultur-
ing [9], serological detection of antigens, such galactoman-
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reproduction in any medium, provided the orpanels [12]. Yet, these methods lack broad-coverage and
are not quantitative [4,13]. Next-generation sequencing is
an effective approach for detecting and characterizing
fungi, but it is expensive, requires complex analyses, and is
not quantitative [14,15].
Measurements of fungal abundance are now typically
performed using biochemical methods targeting ergosterol,
chitin, and fatty acid profiles [16-18], which often require
extraction methods that exclude further molecular analyses
and can lack coverage against major fungal lineages [19].
Alternative approaches such as microscopy [20] and quanti-
tative culture [21,22] are also time-consuming, operator-
dependent, and lack broad-coverage.
To address these limitations, a quantitative molecular
tool that is broad-coverage, sensitive, and specific is
needed [23,24]. Together with qualitative characterization
of fungi, such a tool will provide a comprehensive view of
the fungal microbiota. Additionally, this broad-coverageThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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measure fungal abundance changes over time, in response
to treatment, or among multiple study groups.
Quantitative real-time PCR (qPCR) has been shown to
be more sensitive than culture-based approaches against
a wide range of fungal species [25]. Much progress has
been made in developing qPCR assays that can detect
diverse fungal species [26-30], but we sought to develop
a qPCR assay that would approach universal fungal
coverage. In the current manuscript, we present our
design of a broad-coverage qPCR assay—FungiQuant—
for fungal detection and quantification targeting the fun-
gal 18S rRNA gene. We performed both in silico analysis
based on primer and probe sequence matches to refer-
ence fungal 18S rRNA gene sequences and laboratory
validation following the Minimum Information for Pub-
lication of Quantitative Real-Time PCR Experiments
(MIQE) guidelines [31]. Lastly, we established guidelines
for quantification and detection analysis based results
from triplicate reactions using FungiQuant.
Methods
Design of fungal 18S rRNA gene quantitative real-time
PCR (qPCR) assay
We downloaded fungal 18S rRNA gene sequences alignment
scores and sequence quality scores of >90 and have a length
of 1400 bp or longer from SILVA Release 93 (n = 2,085)
[32]. We summarized the aligned sequences the occurrence
of each allele at each nucleotide position. Alignment posi-
tions with a gap content of >97% were excluded.
We identified a highly conserved 500 bp region for
qPCR assay design. In our assay design, we stipulated
that: 1) primers can only have three or fewer degenerate
bases and 2) the probe contains no degenerate bases.
Using the allele occurrence analysis file, we incorporated
key degenerate bases into each primer and designed a
non-degenerate probe. The primer Tm was calculated
using OligoCalc [33] and the probe Tm was calculated
using the Primer Probe Test Tool from the Primer
ExpressW Software for Real-Time PCR version 3.0 (Applied
Biosystems by Life Technologies, Carlsbad, CA, USA)
(Table 1).
Computational analysis of assay specificity and coverage
A Specificity analysis. We assessed assay specificity




FungiQuant-Prb (6FAM) 50-TGGTGCATGGCCGTT-30 (MGBNsequences from the Genbank nucleotide collection
(nr/nt) [34].
B Collection of 18S rRNA gene sequence for in silico
coverage analysis. From SILVA Release 108, we
downloaded the sequences, sequence ID, and
Genbank accession numbers of all fungal 18S rRNA
gene sequences with sequence quality score of >90
and are 1,400 bp or longer [32]. We extracted the full
Genbank taxonomy for each sequence, which we
concatenated (e.g., at order-level, a taxonomic
identification consists of phylum-subphylum-class-
order). We replaced empty data fields in the
concatenated taxonomy with “unknown”, when
applicable.
COverview of in silico assay coverage analysis. We
performed the in silico coverage analysis using a
stringent and a relaxed criterion, where the stringent
criterion requires full perfect match of both primers
and the relaxed criterion requires perfect match of
the last eight nucleotides at the 3’ end of the primers.
Both conditions require full perfect match of the
probe sequence. For each condition, we determined
the assay’s numerical and taxonomic coverage at the
phylum, sub-phylum, class, order, family, genus, and
species levels. Details for the in silico coverage
analysis can be found in the Additional file 1:
Methodological Details.
Quantification and normalization of FungiQuant plasmid
standards
We utilized a qPCR-based approach to quantify and
normalize the FungiQuant plasmid standards, a C. albicans
18S rRNA gene clone, to a Cp-value equivalent to
109 copies/μl. Details for FungiQuant plasmid normalization
can be found in the Additional file 1: Methodological
Details.
FungiQuant optimization and specificity check
After testing multiple primer and probe concentrations,
the optimized conditions included 10 μl and 5 μl of reac-
tion volumes using 1 μl of template, with the final reac-
tion containing 1.8 μM of each forward and reverse
primer, 225 nM the TaqManW probe, 1% formamide, 1X
PlatinumW Quantitative PCR SuperMix-UDG w⁄ROX




Table 2 Results from the in silico coverage analysis
performed using two sequence matching conditions
Full length primer
& probe (Stringent)
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copies in 10-fold serial dilutions) and no-template controls
in each run, with all reactions performed in triplicates on
the 7900HT Real Time PCR System (Applied Biosystems).
We used the following PCR conditions: 3 min at 50°C for
UNG treatment, 10 min at 95°C for Taq activation, 15 s at
95°C for denaturation and 1 min at 65°C for annealing and
extension x 50 cycles. We determined the Ct-value for each
reaction using a manual Ct threshold of 0.10 and automatic
baseline in the Sequence Detection Systems v2.3 software
(Applied Biosystems). Using the optimized assay condition,
we tested FungiQuant against 0.5 ng, 1 ng, 5 ng, and 10 ng
of human genomic DNA (Promega, Madison, WI, USA)
mixed with the normalized plasmid standards in triplicate
reactions.
FungiQuant laboratory evaluation using diverse fungal
genomic DNA
To assess FungiQuant’s performance against diverse fungi,
we evaluated the assay efficiency and correlation coeffi-
cients against a collection of fungal genomic DNA,
details regarding the fungal DNA collection can be found
in Additional file 1: Methodological Details.
Experimental design
For sensitivity and efficiency analysis, we tested each
fungal genomic DNA in three 10-fold serial dilutions in
triplicate reactions using the optimized 18S qPCR condi-
tions as described above. Using the Ct-value results, we
calculated FungiQuant’s reaction efficiency and correl-
ation coefficient for each species tested.
Limit of detection (LOD) validation
Experimental design
To determine the LOD of FungiQuant for detecting low
concentration fungal DNA, we analyzed no-template
controls (i.e., molecular grade H2O), background control
(i.e., 10 ng, 50ng, and 150ng human DNA), as well as
three low concentration of fungal DNA: a) 1.8 copies,
b) 5 copies, and c) 10 copies of fungal 18S rRNA gene.
Each template was analyzed in 96 replicates in 10 μl and
5 μl reactions using conditions as described above.
Data Analysis
Experimental results using all templates were assessed for:
a) the proportion of determined and undetermined values
and b) the Ct-value distribution among those replicates
with determined values. Using the specificity associated
with the background controls, which provides the most
likely source of contamination and signal noise, the prob-
ability of each triplicate results was calculated under the
null hypothesis that the sample contained no positive
target. The analysis was performed separately for each
reaction volume using an alpha level of 0.05 to determineresults inconsistent with the null. Analysis using the
Ct-value from samples with positive amplification was also
performed using a non-parametric median test to deter-
mine if 1.8 copies, 5 copies, or 10 copies templates could
be differentiated from the no-template and background
controls. The Ct-value data was further assessed to deter-
mine if the average Ct-value is an appropriate estimate of
the true Ct-value in low concentration samples for report-
ing and analysis.
FungiQuant laboratory quantitative validation
Experimental design We followed the Minimum Infor-
mation for publication of Quantitative real-time PCR
Experiments, or the MIQE guidelines, whenever applicable
[31]. We performed additional tests to evaluate FungiQuant
performance when background human DNA is present.
We included seven template conditions: plasmid stan-
dards alone and plasmid standards with 0.5 ng, 1 ng,
5 ng, and 10 ng of human DNA per reaction in 10 μl
reactions, as well as plasmid standards alone and plasmid
standards with 1 ng human DNA in 5 μl reactions. For
each condition assessed, we performed three qPCR runs
to assess reproducibility. In each run, three replicate
standard curves were tested across the 384-well plate to
assess repeatability. Details for the data analysis can be
found in Additional file 1: Methodological Details.
Fungi-to-human DNA threshold ratio calculations
We determined FungiQuant’s minimum threshold of fungi-
to-human DNA ratio using an estimate of average human
18S rRNA gene copy number per genome as 400 copies
[35]. We estimated the diploid human genome as 5,758 Mb
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= 5.887 pg per diploid human genome [37].Results
FungiQuant assay design
We identified three highly conserved regions based on
analysis results of a high-quality 18S rRNA gene multiple
sequence alignments. Within these conserved regions, we
designed two degenerate primers and a non-degenerate
























































 insertae sedis: Sub-phylum Zoopagomycotina
 N/A


























Figure 1 FungiQuant in silico coverage analysis using the relaxed crit
coverage. On the 18S rRNA gene-based phylogeny, each analyzed fungal
on the relaxed criterion. This is presented as a numerator (i.e., the number
genera eligible for sequence matching for the phylum), and the percentagpositioned the probe on the reverse strand, proximal to
the forward primer to create favorable thermodynamic
profile and maximize assay specificity (Additional file 1:
Table S1).in silico analysis of FungiQuant assay coverage using 18S
rRNA gene sequences from 18 fungal subphyla
We performed in silico coverage analysis using a strin-
gent and a relaxed criterion against 4,968 18S rRNA
gene sequences, encompassing 18 fungal subphyla.Basidiomycota: Sub-phylum Ustilaginomycotina
100% (13/13)























































































asiodiomycota: Class Dacrymycetes 
00% (5/5)
asidiomycota: Class Tremellomycetes 
3.94% (31/33)
erion against 993 genera and 9 phyla, demonstrating broad-
phylum is annotated with its genus-level FungiQuant coverage based
of covered genus for the phylum), a denominator (i.e., the number of
e of coverage.
Table 3 FungiQuant sensitivity and reaction efficiency against diverse fungal species
Subphylum Species Reaction efficiency r2
Saccharomycotina Debaryomyces hansenii 101.42% >0.99
Saccharomycotina Lodderomyces elongisporus 93.04% >0.99
Taphrinomycotina Schizosaccharomyces pombe 97.38% >0.99
Saccharomycotina Candida albicans 89.95% >0.99
Pezizomycotina Acremonium strictum 78.95% >0.99
Pezizomycotina Aspergillus flavus 85.96% >0.99
Pezizomycotina Aspergillus fumigatus 81.85% >0.99
Pezizomycotina Aspergillus niger 113.61% >0.99
Pezizomycotina Aspergillus versicolor 89.59% >0.99
Pezizomycotina Aureobasidium pullulans 84.08% >0.98
Pezizomycotina Chaetomium globosum 85.44% >0.99
Pezizomycotina Elaphomyces decipiens 94.78% >0.99
Pezizomycotina Exophiala dermatitidis 76.29% >0.99
Pezizomycotina Fusarium equiseti 89.66% >0.99
Pezizomycotina Fusarium oxysporum 99.70% >0.98
Pezizomycotina Fusarium solani 103.38% >0.99
Pezizomycotina Microsporum canis 84.23% >0.99
Pezizomycotina Neurospora crassa 90.65% >0.99
Pezizomycotina Paecilomyces lilacinus 90.69% >0.99
Pezizomycotina Paecilomyces sinensis 82.30% >0.99
Pezizomycotina Paecilomyces variotii 95.15% >0.99
Pezizomycotina Penicillium marneffei 96.54% >0.99
Pezizomycotina Scedosporium apiospermum 91.58% >0.99
Pezizomycotina Sporothrix schenckii 90.86% >0.99
Pezizomycotina Trichophyton mentagrophytes 92.82% >0.99
Pezizomycotina Trichophyton rubrum 91.43% >0.99
Saccharomycotina Candida famata 90.13% >0.99
Saccharomycotina Candida guilliermondii 82.24% >0.99
Saccharomycotina Candida haemulonii 99.82% >0.99
Saccharomycotina Candida intermedia 81.72% >0.99
Saccharomycotina Candida quercitrusa 98.16% >0.99
Saccharomycotina Candida tropicalis 88.28% >0.99
Saccharomycotina Geotrichum candidum 79.76% >0.99
Saccharomycotina Pichia ohmeri 102.31% >0.99
Saccharomycotina Saccharomycopsis crataegensis 80.98% >0.99
Saccharomycotina Stephanoascus ciferrii 85.84% >0.99
Mucoromycotina Absidia corymbifera 92.33% >0.99
Mucoromycotina Cunninghamella bertholletiae 80.03% >0.99
Mucoromycotina Rhizopus microsporus 89.16% >0.99
Mucoromycotina Rhizopus oryzae 87.96% >0.99
Pezizomycotina Alternaria sp. 103.70% >0.99
Pezizomycotina Cladosporium cladosporioides 92.87% >0.99
Pezizomycotina Cytospora chrysosperma 100.50% >0.99
Pezizomycotina Endoconidioma sp. 89.93% >0.99
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Table 3 FungiQuant sensitivity and reaction efficiency against diverse fungal species (Continued)
Pezizomycotina Geopora sp. 114.45% >0.99
Pezizomycotina Phoma herbarum 91.94% >0.99
Pezizomycotina Xanthomendoza galericulata 94.27% >0.99
Agaricomycotina Agaricus sp. 95.31% >0.99
Agaricomycotina Clavulina coralloides 99.59% >0.99
Agaricomycotina Coprinus sp. 99.70% >0.99
Agaricomycotina Cortinarius sp. 102.68% >0.99
Agaricomycotina Hebeloma crustuliniforme group 91.06% >0.99
Agaricomycotina Melanogaster sp. 102.27% >0.99
Agaricomycotina Pleurotus ostreatus 102.71% >0.99
Agaricomycotina Rhizopogon sp. 107.04% >0.99
Agaricomycotina Sclerogaster xerophilus 92.17% >0.99
Agaricomycotina Sedecula pulvinata 92.26% >0.99
Agaricomycotina Tricholoma populinum 89.53% >0.99
Agaricomycotina Trichosporon asahii 78.03% >0.99
Agaricomycotina Trichosporon asteroides 82.66% >0.99
Agaricomycotina Trichosporon cutaneum 86.66% >0.99
Agaricomycotina Trichosporon dermatis 80.27% >0.99
Agaricomycotina Trichosporon faecale 84.05% >0.99
Agaricomycotina Trichosporon montevideense 77.43% >0.99
Agaricomycotina Trichosporon mucoides 82.87% >0.99
Agaricomycotina Trichosporon ovoides 105.59% >0.99
Pucciniomycotina Rhodotorula mucilaginosa 96.29% >0.99
Pucciniomycotina Rhodotorula slooffiae 99.94% >0.99
Agaricomycotina Lactarius sp. 86.76-89.03% >0.99
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the 18 subphyla had perfect sequence matches to Fungi-
Quant (Table 2). We found that most covered subphyla
were substantially covered on the genus-level as well,
typically with 90% or more of the genera being perfect
sequence matches. Exceptions included Mucoromycotina
(20/36; 55.56%), Kickxellomycotina (6/9; 66.67%), and
Chytridiomycota (9/13; 69.23%). Microspordia and Ento-
mophthoromycotina were the two subphyla without any
perfect sequence matches to FungiQuant (Additional file
2: Figure S1). We found that 1,018 genera (91.4%) and
2,355 species (90.0%) had at least one perfect sequence
match to FungiQuant (Table 2).
When we applied the relaxed criterion, we determined
that FungiQuant covered Entomophthoromycotina
(Figure 1). We also found that 1,057 genera (94.9%) and
2,465 species (94.2%) had at least one perfect sequence
match to FungiQuant (Table 2). In addition, we deter-
mined that FungiQuant had excellent coverage for many
clinically relevant genera such as Cryptococcus spp. (49/49;
100%), Fusarium spp. (7/7; 100%), Mucor spp. (7/7; 100%),Rhizopus spp. (15/15; 100%), and Candida spp. (108/119;
90.76%). Analysis also showed comprehensive coverage
for common environmental genera such as Glomus spp.
(24/25; 96.00%), Gigaspora spp. (5/5; 100%), Trichosporon
spp. (31/31; 100%), and Rhodotorula spp. (22/22; 100%).
Detailed results for the coverage analysis can be found in
Additional file 3: Table S4, Additional file 4: Table S5.
FungiQuant sensitivity against diverse fungal DNA
We tested the sensitivity of FungiQuant against 69
clinical and environmental species from seven subphyla
in the laboratory. We showed that FungiQuant is 100%
sensitive against these diverse species from Agaricomy-
cotina (n = 22), Mucormycotina (n = 4), Pezizomycotina
(n = 29), Pucciniomycotina (n=2), Saccharomycotina
(n = 17), Taphrinomycotina (n = 1), and Ustilaginomyco-
tina (n = 1) (Table 3). All of the fungal species tested
were perfect sequence matches to FungiQuant, and
based on results from three ten-fold dilutions, we found
that the assay reaction efficiencies ranged from 76.29%
to 114.45%., with r2-value of >0.99 (Table 3).
50
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25107 106 105 104 103 102
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0 5 10 15 20 25 30 35 40 45 50
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B
Figure 2 A-B. FungiQuant amplification profiles. The FungiQuant amplification profiles remain consistent, irrespective of reaction volume and
type of DNA template. The amplification profiles of plasmid standards (Fig. 2A) and C. albicans DNA (Fig. 2B) in two reaction volumes (5 μl and
10 μl) are presented.
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against pure plasmids, C. albicans DNA, and templates
with background human DNA
We showed FungiQuant had excellent amplification pro-
files against C. albicans plasmid standards and C. albicans
DNA, with quantitative dynamic range of 25 – 107 copies
and 10 fg – 10 ng C. albicans DNA, respectively
(Figure 2A-B). A list of fungal species that are perfect
matches to C. albicans in the FungiQuant primer and
probe region can be found in Additional file 5: Table S6.
We also showed that FungiQuant had strong reproduci-
bility, even when we added background human DNA. The
inter-run coefficients of variance (CoV) ranged from0.37 – 3.80% and 3.52 – 34.39% for Ct-value and copy
number, respectively. The intra-run average CoV were
0.35 – 2.90% and 1.98 – 23.74% Ct-value and copy number,
respectively (Figure 3, Additional file 6: Figure S2). We
found that 5 μl reactions had greater inter-run CoV than
10 μl reactions (Figure 3). This suggests that the 10 μl
reaction volumes is better suited for quantitative use.
We further determined that FungiQuant’s amplifica-
tion profile and assay dynamic range were not impacted
by the presence of human DNA, at up to 10 ng (Table 4,
Additional file 7: Figure S3A-D). Thus, FungiQuant is
robust quantitatively even when the fungal 18S rRNA
gene is relatively rare as compared to background
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could be applied quantitatively at a ratio of 25:679,464
fungal-to-human 18S rRNA gene copy number.
FungiQuant is robust for low number of fungal 18S rRNA
gene
To validate FungiQuant use for samples with low fungal
DNA and high human DNA, we developed guidelines for
interpreting triplicate reactions. Additional file 1: Table S2
provides the sensitivity and specificity results from Fungi-
Quant evaluation against multiple positive and negative
controls in 10 μl and 5μl reaction volumes. Our analysis
showed that FungiQuant could consistently detect 5 copies
of 18S rRNA gene template, whereas 1.8 copies were
less consistently detected. Nevertheless, further analysis
showed that two or more amplification in triplicate reac-
tions is a reliable indicator of positive fungal DNA detec-
tion, irrespective of Ct-value(s) obtained (Table 5). These
results held for both of the reaction volumes tested.
We also calculated the false negative rate for Fungi-
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Figure 3 A-B. FungiQuant inter- and intra-run coefficient of variation
Ct-value (dashed line), demonstrating the range of CoV, which is lower for
FungiQuant intra-run copy number CoV is consistently below 15% until at
until at 50 copies. The FungiQuant Ct-value CoV is consistently below 10%positive target, a template concentration that provided
relatively poor determination. Using a threshold of ≤ 1
positive amplification used for rejecting triplicate results
as noise, we determined that the false negative rate could
be as high as 80% for samples containing ≤ 1.8 copies when
10 μl reactions are used, and even higher at 87% for sam-
ples analyzed using 5 μl reactions. We found that the
false negative rate decreased significantly for samples
containing 10 and 5 copies, with false negative rates ran-
ging from 0.0% to 0.1%.
We also wanted to determine the utility of Ct-values for
delineating true detection in low concentration samples
from noise. The means and medians of the Ct-values from
amplified wells in the LOD experiments are shown in
Additional file 1: Table S3. The medians of the 10 copies
and 5 copies samples in 10 μl reaction were statistically
lower than water-only or human-only samples. However,
the 1.8 copy samples did not have a median value that
could be discriminated from the negative control distribu-
tions in either reaction volume, despite the approximately




(CoV). FungiQuant CoV is presented for copy number (solid line) and
the 10 μl than the 5 μl reactions. For the 10 μl reactions, the
25 copies, and for the 5 μl reactions, the intra-run CoV is below 20%
, irrespective of reaction volumes.
Table 4 FungiQuant quantitative validation results, obtained using pure plasmid standards and different mixed
templates
Templates tested Assay quantitative dynamic range Average reaction efficiency (SD) r2-value
10 μl Reaction
Plasmid standards-only 25 – 107 copies 91.80% (1.91%) >0.99
Plasmid standards plus 0.5 ng human DNA 25 – 107 copies 93.20% (0.70%) >0.99
Plasmid standards plus 1 ng human DNA 25 – 107 copies 97.02% (4.97%) >0.99
Plasmid standards plus 5 ng human DNA 25 – 107 copies 92.85% (1.33%) >0.99
Plasmid standards plus 10 ng human DNA 25 – 107 copies 91.21% (1.79%) >0.99
C. albicans DNA-only 10 fg – 10 ng 94.75% (2.33%) >0.98
C. albicans DNA plus 1 ng human DNA 10 fg – 10 ng 96.84% (1.93%) >0.99
5 μl Reaction
Plasmid standards-only 25 – 107 copies 92.17% (5.64%) >0.98
Plasmid standards plus 1 ng human DNA 25 – 107 copies 94.21% (2.92%) >0.99
Plasmid standards plus 10 ng human DNA 50 – 108 copies 92.64% (2.39%) >0.99
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distribution of the Ct-values from each condition tested,
we determined the Ct-values for ≥ 5 copies template
(Additional file 8: Figure S4). Based on this, we further
determined that a one standard deviation cutoff could be
used to remove outlying values from a set of triplicate test
result. The Ct-value distribution also supports an aver-
aging approach of non-outlying quantified values to deter-
mine the best estimate of the true Ct-value using the
FungiQuant triplicates in analysis.
Discussion
In the current manuscript, we present our design and
validation of FungiQuant, a broad-coverage TaqManW
qPCR assay for quantifying total fungal load and reprodu-
cibly detecting 5 copies of the fungal 18S rRNA gene usingTable 5 Interpretation of FungiQuant results for
detecting fungal DNA (i.e., rejecting the Null Hypothesis)
based on triplicate 5 μl and 10 μl reactions
Triplicate pattern Probability under the Null Hypothesis










— 0.557triplicate 10 μl reactions. The in silico analysis was an
important component of our validation of FungiQuant
against diverse fungal sequence types, even though
sequence matching is not a perfect predictor of laboratory
performance [38]. Many factors are known to affect reac-
tion efficiency, such as oligonucleotide thermodynamics,
the type of PCR master mix used, and the template DNA
extraction method. Thus, given the range of FungiQuant
reaction efficiency against different fungal species, we
expect FungiQuant to be more accurate in longitudinal
than cross-sectional studies. Background nontarget gen-
omic DNA is another factor known to affect assays target-
ing the conserved rRNA gene [39]. To address this, we
have developed FungiQuant analysis guideline for differ-
entiating random noise from true detection. Lastly, to
address the potential presence of exogenous fungal DNA,
we recommend the use of negative controls at each sam-
ple processing and analysis step.
With respect to FungiQuant LOD, it is worth noting
that a concentration of 1.8 copies/μl of 18S rRNA gene
is the equivalent of 0.5 fg/μl of C. albicans DNA, with
the assumption of 55 18S rRNA gene copy number per
haploid genome [40]. This concentration, using the pub-
lished haploid genome size of 15.185 × 10-3 pg for
C. albicans shows that 0.5 fg is the equivalent of 1/30 of
a single C. albicans genome [40]. Using the same esti-
mates, the 5-copy LOD of FungiQuant is thus the
equivalent of 1.38 fg/μl of C. albicans DNA, or the 1/11
of a single C. albicans genome. Similar conversions of
DNA concentration and genomic equivalents for LOD
estimation for other fungal species can be performed
accordingly; this can help to facilitate estimation of
DNA concentrations and genomic equivalents of fungi
present at levels below other quantitation approaches,
including spectrometric and fluorimetric methods.
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http://www.biomedcentral.com/1471-2180/12/255Use of a probe-based reporting mechanism is an
important feature in FungiQuant in two respects. First,
it enhances the quantitative capability of FungiQuant,
and secondly, improves assay specificity. An example
illustrating the advantage of probe-based reporting is
the comparison of FungiQuant with an intercalating
dye-based qPCR assay, which had amplification efficien-
cies ranging from 67-103% and a LOD of 500pg of fun-
gal DNA [30]. Additionally, the intercalating dye can
generate amplification signal irrespective of amplicon
size or composition.
In summary, we have developed and evaluated a new
broad-coverage qPCR assay—FungiQuant—for diverse
fungal detection and quantification that showed broad
assay coverage and favorable quantitative parameters.
A limitation of the current manuscript is the conversion
from 18S rRNA gene copy number to the number of
cells or biomass. In order to generate an estimated gen-
omic equivalent, improved knowledge of 18S rRNA gene
copy number of diverse fungi is required. And given that
18S rRNA gene copy number varies among fungal spe-
cies and even among strains or over the lifetime of the
fungi [41-43], this challenge will likely to persist. In
addition to the design and validation of a broad-
coverage fungal qPCR assay, our manuscript also sought
to address basic limitations of evaluating combined pri-
mer and probe coverage, as well as generating reference
standards for absolute quantification. Our approach of
evaluating assay coverage by considering the primer and
probe sequences as a single unit is appropriate and
necessary. Additionally, our approach of quantifying
plasmid standards using the intrinsic property of real-
time PCR is another important step for any absolute
quantification experiments using qPCR.
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